Schistosomiasis Treatment Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Schistosomiasis, a parasitic infection caused by Schistosoma species, affects more than 250 million people globally, with the heaviest disease burden concentrated in sub-Saharan Africa. The commercial treatment market is dominated by praziquantel-based therapies, supplemented by oxamniquine in some geographies. Public-sector mass drug administration programs account for the majority of volume, while private retail and institutional channels contribute to overall market value.

• •Approximately 100.5 million people received treatment for schistosomiasis in 2024 out of 253.7 million requiring it, according to WHO data.
• •Praziquantel remains the WHO-recommended first-line therapy and the cornerstone of most national treatment programs.
• •Market value estimates for this segment vary widely across analysts, ranging from under USD 100 million to over USD 1.6 billion depending on scope and methodology.

Expansion of WHO-led preventive chemotherapy campaigns is the single largest demand driver, as endemic countries scale up mass drug administration toward elimination targets. Rising donor commitments through partnerships such as the NTD Roadmap 2030 continue to underwrite treatment procurement in low-income settings. Growing awareness of schistosomiasis-related morbidity, including its links to anemia, stunting, and increased HIV susceptibility, is reinforcing political and financial commitment to control programs.

• •WHO's NTD Roadmap 2030 targets elimination of schistosomiasis as a public health problem in 67 endemic countries.
• •Increased pharmaceutical donations and co-financing mechanisms have expanded access to praziquantel in sub-Saharan Africa.
• •Greater integration of schistosomiasis treatment with school health and water, sanitation, and hygiene (WASH) initiatives supports sustained demand.

By drug class, the market is led by anthelmintics, particularly praziquantel, with smaller segments for oxamniquine and complementary therapies addressing symptoms such as organ damage and co-infections. By distribution channel, public health programs, donor-funded initiatives, and hospital pharmacies dominate volume, while retail pharmacies hold a modest share. Geographically, sub-Saharan Africa accounts for the largest share of demand due to high endemicity, with secondary markets in parts of the Middle East, South America, and Southeast Asia.

• •Sub-Saharan Africa represents the dominant regional market, reflecting more than 90% of global schistosomiasis cases.
• •School-based deworming programs serve as the primary delivery channel for pediatric treatment in endemic areas.
• •Brazil, China, the Philippines, and select Middle Eastern nations represent smaller but growing treatment markets.

What are the recent trends and outlook?

A defining trend is the shift toward elimination-oriented strategies, including expanded mass drug administration, improved diagnostics, and integration with WASH infrastructure. Innovation in pediatric formulations and combination therapies is expected to broaden treatment eligibility, particularly for preschool-aged children who have historically been underserved. Donor fatigue, climate-related shifts in snail habitat distribution, and potential resistance pressure on praziquantel represent ongoing risks that could shape the market trajectory through the end of the decade.

• •Development of pediatric praziquantel formulations aims to close the treatment gap for children under five years old.
• •Climate change is altering the geographic range of freshwater snail vectors, potentially expanding transmission into new areas.
• •Surveillance for reduced praziquantel efficacy is increasing, though clinically confirmed resistance remains rare.